Brentuximab vedotin + Pembrolizumab
Phase 2RecruitingInterest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
T-Cell Lymphoma
Conditions
T-Cell Lymphoma
Trial Timeline
Jul 10, 2023 → Jul 30, 2028
NCT ID
NCT05313243About Brentuximab vedotin + Pembrolizumab
Brentuximab vedotin + Pembrolizumab is a phase 2 stage product being developed by Merck for T-Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05313243. Target conditions include T-Cell Lymphoma.
What happened to similar drugs?
5 of 10 similar drugs in T-Cell Lymphoma were approved
Approved (5) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05313243 | Phase 2 | Recruiting |
| NCT04609566 | Phase 2 | Completed |
| NCT04795869 | Phase 2 | Withdrawn |
Competing Products
20 competing products in T-Cell Lymphoma